QuidelOrtho Slashes 2026 Guidance, Revenue and EPS Cut Sharply
QDEL sits 34% above its 52-week low of $9.92.
Summary
QuidelOrtho reported Q2 revenue of $631M, up 3% reported, but slashed full-year guidance across the board. Revenue guidance dropped to $2.52-$2.60B from $2.70-$2.75B, adjusted EBITDA to $540-$560M from $615-$630M, and adjusted EPS to $0.65-$0.90 from $1.80-$2.00. Free cash flow guidance was withdrawn entirely. The company cited China IVD pricing headwinds and a softer respiratory environment. This follows a Q1 net loss and negative operating cash flow, and the recent appointment of a new CFO. The magnitude of the guidance cut—especially the EPS reduction of over 50% at the midpoint—signals deeper operational challenges than previously disclosed. The withdrawal of cash flow guidance raises liquidity concerns given the already strained balance sheet.
At the time of this announcement, QDEL was trading at $13.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $9.92 to $35.58. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: PR Newswire.